Executive Summary
TAVR durability past year seven now sits on published PARTNER 3 seven-year data in NEJM — mean gradients 13.1 mm Hg for TAVR vs 12.1 mm Hg for surgery, EOAs 1.9 vs 1.8 cm² — with a simultaneous commentary in Journal of Thoracic Disease reminding us that a decade is within reach but not the destination. The FTC hit Edwards with a $10M penalty tied to the JC Medical acquisition the same week its shares brushed a 52-week high on a favorable Medicare coverage proposal, and a National Inpatient Sample analysis shows prior VTE independently raises in-hospital mortality nearly six-fold after TAVR and TMVR — which tightens the case for TAVR in low-risk patients on efficacy grounds while complicating both selection and the political optics of the Edwards franchise.
- PARTNER 3 seven-year composite endpoint and hemodynamics remain comparable between TAVR and SAVR, but bench-vs-body durability past year 10 is still unproven, per Shuhaiber's Journal of Thoracic Disease commentary.
- Prior VTE carries an adjusted OR of 5.96 for in-hospital death after TAVR (n=295,795) and 5.58 after TMVR (n=5,145) in a 2016–2020 NIS analysis (J Thromb Thrombolysis).
- MAUDE post-market surveillance flags device detachment/malfunction as the dominant TEER adverse event, more common with MitraClip than PASCAL (47.98% vs 20.83%, P=0.005), though passive reporting caveats apply (J Thorac Dis).
- Angiography-derived QFR shows pooled sensitivity 0.79 and specificity 0.88 vs invasive FFR in TAVR candidates across five studies — good, not definitive, given hemodynamic instability of the reference standard (J Invasive Cardiol).
- Edwards paid $10M to settle FTC charges over failure to file HSR notification on the JC Medical (JenaValve) transaction, with Genesis MedTech adding $2M (MD+DI).
What to watch: Edwards Q2 earnings on July 23 will be the first opportunity to hear management address both the FTC settlement and the Medicare coverage tailwind in the same call.
Aortic Valve (TAVR/TAVI)
The PARTNER 3 seven-year readout gives TAVR its cleanest low-risk durability story to date, but the field is not done arguing about year 10. The NEJM update (industry-sponsored, sponsor-manufactured device) shows comparable death/stroke/rehospitalization composites and near-identical hemodynamics — mean gradient 13.1 vs 12.1 mm Hg, EOA 1.9 vs 1.8 cm². ESC 2025 already moved to a TAVI-preferred posture at age ≥70 with tricuspid anatomy (Class I); ACC/AHA 2020 still holds the SAVR-preferred line under 65 on durability grounds. A companion editorial in Journal of Thoracic Disease makes the surgical counterpoint plainly: seven years is not a decade, and a decade is not a lifetime for a 65-year-old. [NOTABLE] New NIS data show prior VTE independently increases in-hospital mortality after TAVR nearly six-fold (OR 5.96, 95% CI 4.31–8.22) — a signal that risk-stratification cannot lean on STS alone. A JACC Case Reports vignette adds that emergency TAVR in a 51-year-old with bicuspid AS in cardiogenic shock is feasible, though both guidelines still rate BAV-TAVI as Class IIb. Coronary physiology in this population remains imperfect: QFR sensitivity 0.79 / specificity 0.88 against invasive FFR, with no stable reference standard across pre- and post-TAVI hemodynamic states.
Mitral Valve (MitraClip, PASCAL, TMVR)
Post-market surveillance narrows the practical gap between MitraClip and PASCAL — but not on the axis Abbott would prefer. The MAUDE analysis of 518 reports from September 2022 through August 2025 finds device detachment or malfunction is the dominant adverse event, and it is more than twice as common with MitraClip (47.98% vs 20.83%, 95% CI 1.408–13.855; P=0.005). Valve apparatus tears, embolization, cardiogenic shock, and pericardial effusion did not differ significantly. The authors correctly label this "hypothesis-degenerating" — passive reporting, no denominators, cohort imbalance — but referring clinicians will read the headline first. This surveillance signal lands with ESC 2025 having upgraded TEER for ventricular secondary MR to Class I, LOE A off COAPT and RESHAPE-HF2, while ACC/AHA 2020 still holds at Class IIa. A separate JACC Case Reports series describes combined M-TEER plus paravalvular leak closure for a dehisced surgical annuloplasty ring in an 85-year-old — feasible bailout when redo surgery is prohibitive, but a reminder that complex mixed MR after failed repair remains a small-N, single-operator problem, not a category.
Tricuspid Valve (TriClip, TTVR)
Heterotopic tricuspid replacement is the field's answer to the patients TRILUMINATE and TRISCEND II excluded. The UNICA system review in Future Cardiology describes a single-stent, double-valve platform positioned outside the native annulus for severe TR patients ineligible for annular repair or replacement — early data show high technical success and short procedural times, but the paper is a narrative review, not a controlled trial. ESC 2025 already rates transcatheter TV treatment as Class IIa, LOE A for high-risk symptomatic severe TR; ACC/AHA 2020 remained silent on transcatheter TR therapy because the pivotal trials had not read out. The surgical counterpoint has hardened in Europe: ESC upgraded TV surgery for symptomatic severe primary TR to Class I this year, and the too-late-referral problem — historical isolated TV surgery mortality of 8–20% — is the reason heterotopic devices exist in the first place. UNICA sits in the anatomic-orphan bucket alongside patients with prohibitive annular calcification or failed prior TEER. Prospective data on durability and functional trajectory beyond one year remain the missing piece.
Surgical vs. Transcatheter Comparisons
No head-to-head randomized comparisons published today. The day's transcatheter findings — PARTNER 3 at seven years, MAUDE TEER surveillance, UNICA heterotopic TV — all sit against surgical comparators where long-term durability remains the surgeon's strongest card. On the aortic side, the Thoracic and Cardiovascular Surgeon reports a 15.5% incidence of postoperative cognitive dysfunction after complex aortic arch replacement (n=103, single-center), with age, female sex, and antegrade cerebral perfusion time as independent predictors and no midterm survival penalty — a reminder that the surgical morbidity conversation in aortic disease extends well beyond the valve itself.
Preprint Highlights
A medRxiv preprint from Dhingra and Khera's group deploys autonomous code-writing agents to iteratively improve AI-ECG models for structural heart disease detection, with AUROC gains of 0.006–0.039 on held-out and cross-institution evaluations. Specificity at 90% sensitivity rose up to 7.1 percentage points. Not peer-reviewed, and the governance model matters more than the deltas — but this is the direction of travel for AI-ECG screening tools that will feed structural heart programs upstream of imaging.
Device & Technology
Edwards' SAPIEN 3 Ultra RESILIA platform is now the only TAVR device with published seven- and ten-year durability data, per the Cardiovascular Business piece (note: sponsored content). HeartBeam's patent expansion for cardiac monitoring now formally includes structural heart disease indications (citybuzz) — a screening play, not a therapy, but relevant to referral pipelines. TCTMD reports that single-heartbeat CCTA acquisition is diagnostic in many young, low-risk patients — a workflow gain for pre-TAVI planning at high-volume centers.
Regulatory & Policy
[NOTABLE] The FTC extracted $10M from Edwards Lifesciences and $2M from Genesis MedTech to settle allegations that Edwards' acquisition of JC Medical (parent of JenaValve) violated Hart-Scott-Rodino notification requirements (MD+DI; Moomoo/Yahoo). Small dollars for Edwards, but this is the aortic regurgitation franchise — JenaValve's Trilogy device is Edwards' AR play — and the settlement puts an antitrust asterisk on the deal that closes in the same quarter the company hits a 52-week high. Edwards also reportedly rallied on a favorable Medicare coverage proposal the same week — likely tied to asymptomatic AS or moderate-AS expansion, though details were not released today.
Industry & Market
Edwards' week: FTC penalty, 52-week high, Baird nudging its price target to $94 from $87 (still Neutral), and PARTNER 3 seven-year data circulating in the trade press. Structural heart remains the strategic core; the FTC action does not disturb the JC Medical assets, only the paperwork around them. The Anteris (AVR.AX) chart continues to reflect the pre-clinical / early-clinical DurAVR story — up 81% over six months on limited data, and reader beware.
Financial Analysis
The clinical–market linkage today is Edwards. Seven-year PARTNER 3 durability data give referring cardiologists cover to send younger low-risk patients for TAVR, which is the volume story underneath the Medicare coverage speculation lifting the stock. The FTC settlement is a rounding error on Edwards' ~$52B market cap, but the JC Medical / JenaValve integration is the AR growth vector for 2026–2027 — and the regulatory friction slows the go-to-market narrative. Baird's Neutral rating at $94 reflects the tension: durability data is validated, valuation is stretched, and the next catalyst (Q2 earnings, July 23) has to deliver on both TAVR volumes and clarity on the AR portfolio timeline.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Last close ~$92.21; six-month range $74.66–$96.29; 52-week high $96.29 touched this week
- Market cap $51.9B; trailing P/E 49.5; forward P/E 26.75; beta 0.85
- Analyst consensus target $98.58 (26 analysts, Buy); Baird raised to $94, held Neutral
- Next earnings July 23; EPS est. $0.74, revenue est. $1.70B
- This week: $10M FTC settlement over JC Medical HSR notification failure, 52-week high on Medicare coverage proposal, PARTNER 3 seven-year data circulating
Medtronic (MDT)
- Last close ~$83.87; six-month range $72.65–$103.71; underperforming vs EW year-to-date
- Market cap $101.5B; trailing P/E 22.4; forward P/E 12.38; beta 0.58
- Analyst consensus target $97.00 (Buy); next earnings August 18, EPS est. $1.39, revenue est. $9.55B
- Evolut franchise trailing SAPIEN on published long-term durability data cadence
Abbott (ABT)
- Last close ~$93.93; six-month range $81.97–$123.64; down significantly from January highs
- Market cap $155.0B; trailing P/E 24.92; forward P/E 14.69; beta 0.61
- Analyst target $116.40 (Buy); next earnings July 16, EPS est. $1.28, revenue est. $12.52B
- MitraClip franchise faces MAUDE detachment/malfunction signal; TriClip franchise sits against ESC 2025 Class IIa transcatheter TV upgrade — competitive but not sole beneficiary